Compare Neurocrine Biosciences Inc (NBIX) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Quanta Services Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while Quanta Services Inc trades at $695.67 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 7.2× Neurocrine Biosciences Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Quanta Services Inc for 62 Days on average.
| NBIX | PWR | |
|---|---|---|
Market Cap | $14.36B | $103.03B |
Volume | 1,237,180 | 977,892 |
Sector | Health | Industrials |
52-Week High | $185.50 | $785.24 |
52-Week Low | $123.10 | $412.21 |
Typical Hold Time | 23 Days | 62 Days |
Enterprise Value | $14.37B | $109.13B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
PWR trades at $701.07, down 2.57% on the day, but maintains a bullish technical stance with strong support near $690. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $802.08 implying significant upside.
The outlook for PWR is favorable, driven by a record $53B backlog and exposure to AI infrastructure spending. Key risks include execution challenges on large projects and rising debt levels. With 75% of analysts rating it a Buy and strong institutional support, the stock presents a growth opportunity, but investors should monitor cash flow trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
